Kaempferia parviflora Ethanol Extract, a Peroxisome Proliferator-Activated Receptor Ligand-binding Agonist, Improves Glucose Tolerance and Suppresses Fat Accumulation in Diabetic NSY Mice

被引:20
|
作者
Ochiai, Masaru [1 ]
Takeuchi, Toshiki [2 ]
Nozaki, Tsutomu [3 ]
Ishihara, Ken-o [3 ]
Matsuo, Tatsuhiro [2 ]
机构
[1] Kitasato Univ, Sch Vet Med, 23-35-1 Higashi, Towada, Aomori 0348628, Japan
[2] Kagawa Univ, Fac Agr, Kita Ku, 2393 Ikenobe, Miki, Kagawa 7610795, Japan
[3] BHN Co Ltd, Chiyoda Ku, 1-16 Kandanishiki, Tokyo 1010054, Japan
关键词
fat accumulation; glucose tolerance; Kaempferia parviflora; methoxy flavone; PPAR; ETHYL-ACETATE EXTRACT; TISSUE DISTRIBUTION; INSULIN-RESISTANCE; PANCREATIC LIPASE; PPAR-GAMMA; 5,7-DIMETHOXYFLAVONE; MOUSE; RAT; POLYMETHOXYFLAVONOIDS; PHARMACOKINETICS;
D O I
10.1111/1750-3841.14437
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
This study assessed the effect of Kaempferia parviflora, also known as black ginger (BG), and its ethanol extract (BGE) on peroxisome proliferator-activated receptor (PPAR) agonistic activity, glucose tolerance, fat accumulation, and lipids-induced hypertriglyceridemia in mice. PPAR ligand-binding capacity in vitro and polymethoxy flavone contents were highly observed in organic solvent extracts. In an animal experiment A, male diabetic Nagoya-Shibata-Yasuda mice were divided into five dietary groups and fed each diet for 8 weeks: AIN-93G diet (low-fat [LF] diet), high-fat (HF) diet, HF diet supplemented with 1% BG, HF diet supplemented with 0.19% BGE, and HF diet supplemented with pioglitazone (PPAR agonist, 3 mg/kg/day) as a PPAR agonistic positive control. As determined from glucose and insulin tolerance tests, plasma glucose levels were improved in the BG and BGE groups. The BGE extract suppressed fat accumulation in adipose tissues, liver, and muscles without changing the plasma adiponectin level. In an animal experiment B, in order to investigate the effect of BG and BGE on lipid-induced hypertriglyceridemia, male ddY mice were divided into three test groups: control, BG-administered group (500 mg/kg), and BGE-administered group (100 mg/kg). The plasma triacylglycerol level was not different among the groups during the lipids administration test. These results conclude that the BGE extract containing several kinds of polymethoxy flavones showed PPAR ligand-binding capacity in vitro and prevented obesity and insulin resistance independent of adiponectin secretion in mice.
引用
收藏
页码:339 / 348
页数:10
相关论文
共 29 条
  • [1] New Peroxisome Proliferator-Activated Receptor Agonist (GQ-11) Improves Wound Healing in Diabetic Mice
    Silva, Jacqueline C.
    Pitta, Marina G. R.
    Pitta, Ivan R.
    Koh, Timothy J.
    Abdalla, Dulcineia S. P.
    ADVANCES IN WOUND CARE, 2019, 8 (09) : 417 - 428
  • [2] Identification of Binding Regions of Bilirubin in the Ligand-Binding Pocket of the Peroxisome Proliferator-Activated Receptor-A (PPARalpha)
    Gordon, Darren M.
    Hong, Stephen H.
    Kipp, Zachary A.
    Hinds, Terry D., Jr.
    MOLECULES, 2021, 26 (10):
  • [3] Different structures of the two peroxisome proliferator-activated receptor gamma (PPARγ) ligand-binding domains in homodimeric complex with partial agonist, but not full agonist
    Ohashi, Masao
    Oyama, Takuji
    Miyachi, Hiroyuki
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (13) : 2639 - 2644
  • [4] Pharmacological Activation of Peroxisome Proliferator-activated Receptor δ Improves Insulin Resistance and Hepatic Steatosis in High Fat Diet-induced Diabetic Mice
    Wu, H. -T.
    Chen, C. -T.
    Cheng, K. -C.
    Li, Y. -X.
    Yeh, C. -H.
    Cheng, J. -T.
    HORMONE AND METABOLIC RESEARCH, 2011, 43 (09) : 631 - 635
  • [5] Identification of an alternative ligand-binding pocket in peroxisome proliferator-activated receptor gamma and its correlated selective agonist for promoting beige adipocyte differentiation
    Tian, Qiang
    Wang, Miaohua
    Wang, Xueting
    Lei, Zhenli
    Ahmad, Owais
    Chen, Dianhua
    Zheng, Wei
    Shen, Pingping
    Yang, Nanfei
    MEDCOMM, 2024, 5 (07):
  • [6] Abscisic Acid Regulates Inflammation via Ligand-binding Domain-independent Activation of Peroxisome Proliferator-activated Receptor γ
    Bassaganya-Riera, Josep
    Guri, Amir J.
    Lu, Pinyi
    Climent, Montse
    Carbo, Adria
    Sobral, Bruno W.
    Horne, William T.
    Lewis, Stephanie N.
    Bevan, David R.
    Hontecillas, Raquel
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (04) : 2504 - 2516
  • [7] Tesaglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance
    Schuster, Herbert
    Fagerberg, Bjorn
    Edwards, Sion
    Halmos, Tamas
    Lopatynski, Jerzy
    Stender, Steen
    Birketvedt, Grethe Stoa
    Tonstad, Serena
    Gause-Nilsson, Ingrid
    Halldorsdottir, Sigrun
    Oehman, K. Peter
    ATHEROSCLEROSIS, 2008, 197 (01) : 355 - 362
  • [8] Peroxisome proliferator-activated receptor-α agonist, Wy 14 643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis
    Larter, Claire Z.
    Yeh, Matthew M.
    Van Rooyen, Derrick M.
    Brooling, John
    Ghatora, Kamaljit
    Farrell, Geoffrey C.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (02) : 341 - 350
  • [9] A Selective Peroxisome Proliferator-Activated Receptor α Agonist, CP-900691, Improves Plasma Lipids, Lipoproteins, and Glycemic Control in Diabetic Monkeys
    Wagner, Janice D.
    Shadoan, Melanie K.
    Zhang, Li
    Ward, Gina M.
    Royer, Lori J.
    Kavanagh, Kylie
    Francone, Omar L.
    Auerbach, Bruce J.
    Harwood, H. James, Jr.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 333 (03) : 844 - 853
  • [10] Peroxisome Proliferator-activated Receptor-γ (PPARγ) Agonist Improves Coronary Artery Endothelial Function in Diabetic Patients with Coronary Artery Disease
    Yu, J.
    Zhang, Z.
    Li, Z.
    Feng, X.
    He, L.
    Liu, S.
    Mao, J.
    Wang, G.
    Wang, X.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2010, 38 (01) : 86 - 94